Description:
Princeton University Invention #
08-2484
Cisplatin is a
leading chemotherapy agent; however its effectiveness is limited by its severe
side effects. Researchers at Princeton University and the University of
Medicine and Dentistry New Jersey, Department of Chemistry and Department of
Pathology and Laboratory Medicine, respectively have synthesized photoreducible
complexes incorporating cisplatin.
These complexes
contain an intervalent charge transfer band that when irradiated with visible
light undergo a charge transfer reaction forming cisplatin. These
complexes can act as masking agents for photoaction therapy as a way to decrease
side effects of cisplatin treatment. Water soluble, photoactivatable
complexes have been synthesized and have been tested in vitro to undergo
the desired photochemistry. Further in vivo tests are
planned.
The current use of cisplatin is limited by its toxicity in spite of its
effectiveness in the treatment of cancer such as testicular, ovarian, and head
and neck tumors. This technology may allow for increased efficacy in the use of
greater doses of cisplatin without the severe side effects
Princeton is
currently seeking commercial partners for the further development and
commercialization of this opportunity. Patent protection is
pending.
For more information on Princeton
University invention # 08-2484 please contact:
Laurie Tzodikov
Office of Technology Licensing and Intellectual Property
Princeton University
4 New South Building
Princeton, NJ 08544-0036
(609) 258-7256
(609) 258-1159 fax
tzodikov@princeton.edu